Table 3.
Cancer Prevalence in the ICL Cohort as Compared with Expected Cases.*
| Variable | Histotype | Cases in ICL Cohort† | Expected Cases | P Value |
|---|---|---|---|---|
| number of patients | ||||
| Any prevalent or incidental cancer | 13 | 5.412 | 0.004 | |
|
| ||||
| Incidental cancer only | 11 | 5.412 | 0.02 | |
|
| ||||
| Type of cancer | ||||
|
| ||||
| Anus or anal canal | Squamous-cell carcinoma | 2 | 0.020 | |
|
| ||||
| Breast | Lobular or ductal carcinoma | 2 | 1.078 | |
|
| ||||
| Thyroid | Papillary thyroid carcinoma | 2 | 0.297 | |
|
| ||||
| Lung | Squamous-cell carcinoma | 1 | 0.186 | |
|
| ||||
| Prostate | Adenocarcinoma | 1 | 1.491 | |
|
| ||||
| Non-Hodgkin’s lymphoma | Marginal B-cell lymphoma, mycosis fungoides | 2 | 0.258 | |
|
| ||||
| Oral cavity or pharynx | Squamous-cell carcinoma | 2 | 0.154 | |
|
| ||||
| Vulvovagina | Squamous-cell carcinoma | 1 | 0.014 | |
|
| ||||
| Kaposi’s sarcoma | Cutaneous or visceral | 1 | 0.015 | |
*
Shown is the cancer prevalence in the cohort of patients with idiopathic CD4 lymphocytopenia (ICL) as compared with expected cases in the general population in the Surveillance, Epidemiology, and End Results Program as matched according to age and sex.
†
A total of 14 separate invasive cancers were diagnosed in 13 patients.